Growth hormone is released from the pituitary gland in natural pulses throughout the day, orchestrating processes from tissue maintenance to metabolic regulation. Rather than introducing synthetic growth hormone directly, a class of research peptides works by signaling the body's own pituitary to release GH through its native pathways. Two peptides have become central to this area of investigation: Ipamorelin and Tesamorelin.
Ipamorelin
What it is: A selective five-amino-acid growth hormone secretagogue that triggers natural GH release from the pituitary gland without significantly affecting cortisol or prolactin levels.
How It Works
What Researchers Study It For
Common Research Protocols
In published research, Ipamorelin is supplied as a lyophilized powder and reconstituted with bacteriostatic water. It is typically administered via subcutaneous injection.
Community Interest Areas
Ipamorelin has generated significant research interest due to its selectivity profile. Unlike earlier secretagogues, it does not appear to significantly elevate cortisol, ACTH, or prolactin in research settings. This makes it a preferred compound in studies investigating isolated GH signaling without confounding hormonal variables. It is frequently paired with CJC-1295 in combined protocols.
Tesamorelin
What it is: A synthetic analog of growth hormone-releasing hormone (GHRH) consisting of the full 44-amino-acid GHRH sequence with a trans-3-hexenoic acid modification that improves stability.
How It Works
The key difference between Ipamorelin and Tesamorelin: Ipamorelin acts through the ghrelin receptor (GHS-R1a) to trigger a GH pulse, while Tesamorelin acts through the GHRH receptor to stimulate both production and release of GH. They use entirely separate signaling pathways to achieve a similar outcome.
What Researchers Study It For
Common Research Protocols
Tesamorelin is reconstituted from lyophilized powder and administered via subcutaneous injection. It is one of the few GH-releasing peptides that has undergone extensive clinical evaluation, including large-scale trials examining its effects on trunk fat in the context of HIV-associated lipodystrophy. Research protocols typically involve daily administration over multi-week study periods. Source
Community Interest Areas
Tesamorelin draws substantial research interest in metabolic and body composition studies, particularly in models investigating visceral fat accumulation. Because it works through the GHRH receptor rather than the ghrelin pathway, it is often explored alongside ghrelin-mimetic peptides like Ipamorelin in dual-pathway research protocols designed to study synergistic GH release.
How They Compare
Key Takeaways
- Ipamorelin is studied for its selective activation of the ghrelin receptor pathway, triggering endogenous GH pulses without significantly elevating cortisol or prolactin
- Tesamorelin works through the GHRH receptor to stimulate both the production and release of growth hormone, with extensive clinical-stage research in metabolic contexts
- The two peptides use entirely separate receptor pathways, which is why researchers frequently study them together in dual-mechanism protocols
- Both compounds promote endogenous GH release rather than introducing exogenous growth hormone, preserving the body's natural pulsatile secretion pattern and feedback regulation
- The statements made on this website have not been evaluated by the U.S. Food and Drug Administration (FDA). All products sold by 33 Degrees of Healing are provided strictly for research, laboratory, and investigational purposes only.
Related Research Compounds
Read the Full Scientific Review →
Sources
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998. PubMed
- Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007. PubMed
- Stanley TL, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation. JAMA. 2014. PubMed
- Anderson NB, et al. Ipamorelin as a new GH secretagogue with improved safety profile. Growth Horm IGF Res. 2001. PubMed
This article is for educational and research purposes only. It is not intended as medical advice. The compounds discussed are research chemicals not approved by the FDA for human use. Always consult qualified professionals and review current regulations before conducting any research.